Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe record history now includes a new revision entry v3.4.3 and removes the previous revision v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe study record now shows a Completed status with updated Study Status and Recruitment Status, and new References and Contacts/Locations sections have been added. The previous government-funding operating status notice has been removed.SummaryDifference1.0%

- Check41 days agoChange DetectedAdded a site-wide funding-status notice and updated the revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check48 days agoChange DetectedThe history page now displays a glossary, uses green/red highlights to show additions and deletions, and updates the revision label to v3.4.0 (replacing v3.3.4), with minor textual tweaks like capitalization of 'FEAR Act Data'.SummaryDifference0.6%

- Check84 days agoChange DetectedFooter metadata updated with Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check106 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to study content or page functionality are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.